Prestige Consumer Healthcare Q3 Earnings Call Highlights

Core Insights - Prestige Consumer Healthcare reported solid fiscal third-quarter results despite a challenging consumer environment, with revenue of $283.4 million, down 2.4% year-over-year, primarily due to lower sales in eye and ear care products [3][4][6] - The company narrowed its full-year fiscal 2026 revenue outlook to approximately $1.1 billion and reaffirmed expectations for free cash flow of at least $245 million [4][6][19] - Management highlighted ongoing supply constraints in the Clear Eyes brand but noted improvements in supply and production capabilities, expecting continued sequential increases through calendar 2026 [7][9][8] Financial Performance - Gross margin for the third quarter was reported at 55.5%, with adjusted diluted EPS at $1.14, consistent with prior guidance [1][4] - Year-to-date results showed an organic revenue decline of 3.9%, with North America segment revenue down 4.4% excluding foreign exchange [11] - Despite lower sales, the company improved profitability, with a gross margin of 55.7% for the first nine months, up 50 basis points from the prior year [12][14] Capital Allocation - The company closed the Pillar5 acquisition for just over $110 million and repurchased more than $150 million of stock year-to-date, representing nearly 5% of shares outstanding [5][16] - Prestige ended the quarter with approximately $1 billion in net debt, equating to a leverage ratio of 2.6x, emphasizing flexibility in cash deployment for brand investments and M&A [15][17] Market Trends and Consumer Behavior - Management characterized the consumer backdrop as dynamic, with ongoing changes in shopping habits influenced by tariffs, inflation, and other factors [2] - E-commerce consumption grew over 10% in the third quarter, driven by consumer demand for broad selection and pricing transparency [22] - The company is adapting its marketing strategies to align with changing consumer shopping behaviors, particularly as Clear Eyes products become more available [22] Category Performance - GI brands like Fleet and Dramamine performed well, while analgesics faced unexpected weakness due to acetaminophen-related announcements, with Prestige's brands down a couple of points [21] - Management expects improvements in the analgesics category in the fourth quarter, despite current challenges [21]